KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
View Article
KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors
View Article
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
View Article
KeifeRx to Present at the BIO CEO & Investor Conference
View Article
KeifeRx to Present at BioFuture 2022
View Article
KeifeRx to Present at BIO International Convention 2022
View Article
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
View Article
KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer’s Disease
View Article
KeifeRx Builds Leadership Team with Announcement of Chris Hoyt as Chief Executive Officer
View Article
Nilotinib Appears Safe and Affects Biomarkers in Alzheimer’s Disease Clinical Trial Georgetown University Medical Center
View Article
Georgetown Offers Multiple Clinical Trials for People with Lewy Body Dementia Georgetown University
View Article
Cures Within Reach Funds Huntington’s Disease Clinical Trial with Nilotinib at Georgetown Georgetown University
View Article
Agent Clears Toxic Proteins, Reduces Inflammation and Improves Cognition in Neurodegeneration Models Georgetown University
View Article
Georgetown Announces Phase II Clinical Trial of Nilotinib for Parkinson’s Disease Georgetown University
View Article
Georgetown receives FDA clearance to conduct clinical trial with nilotinib in Alzheimer’s disease Georgetown University
View Article
Keiferx CEO on new method for treating Alzheimer’s, neurodegenerative disease
View Article
Disposing Toxic Proteins to Treat Neurodegenerative Diseases
View Article
Parkinson’s Disease Trial Reveals Defects in Blood-Brain Barrier
View Article
Vascular defects appear to underlie the progression of Parkinson’s disease
View Article
CML Drug Nilotinib Shows Early Effects in Alzheimer’s Disease
View Article
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease – Audio
View Article
Novel agent flips on garbage disposal in neurons, eliminating toxic brain proteins in mice
View Article
Could a Pfizer Cancer Drug be a Treatment for a Form of Dementia? Georgetown University Launches Clinical Trial to Find Out
View Article
Researchers Decode How Cancer Drug Works in Brains of Parkinson’s Disease Patients
View Article
Leukemia Drug Nilotinib Can Cure Parkinson’s, Alzheimer’s & Dementia As Well
View Article
Cancer Drug That Might Slow Parkinson’s, Alzheimer’s Headed For Bigger Tests
View Article
Georgetown to Lead Phase 2 Study of Cancer Drug in Treating Alzheimer’s
View Article